Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal Weight But Not Obese Women

Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal Weight But Not Obese Women 2017-03-29, 9*11 AM
J Clin Endocrinol Metab. 2016 Jan; 101(1): 324333. PMCID: PMC4701838

Published online 2015 Nov 2. doi: 10.1210/jc.2015-2913
Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal

Weight But Not Obese Women
Zain A. Al-Safi, Huayu Liu, Nichole E. Carlson, Justin Chosich, Mary Harris, Andrew P. Bradford, Celeste Robledo,
Robert H. Eckel, and Alex J. Polotsky
Department of Obstetrics and Gynecology (Z.A.A., J.C., A.P.B., C.R., A.J.P.), University of Colorado School of Medicine, Aurora, Colorado
80045; Department of Biostatistics and Informatics (H.L., N.E.C.), Colorado School of Public Health, Aurora, Colorado 80045; Department of
Food Science and Human Nutrition (M.H.), Colorado State University, Fort Collins, Colorado 80523; and Department of Medicine (R.H.E.),
University of Colorado School of Medicine, Aurora, Colorado 80045
Corresponding author.
Address all correspondence and requests for reprints to: Alex J. Polotsky, MD, MS, University of Colorado Anschutz Medical Campus,
Department of Obstetrics and Gynecology, 12631 East 17th Avenue, B198-3, Aurora, CO 80045. E-mail: alex.polotsky@ucdenver.edu.
Received 2015 Jul 17; Accepted 2015 Oct 23.
Copyright 2016 by the Endocrine Society
Abstract
Context:
Dietary omega-3 fatty acids delay ovarian aging and promote oocyte quality in mice.
Objective:
To test whether dietary supplementation with omega-3 polyunsaturated fatty acids (PUFA) modulates
reproductive hormones in reproductive-age women.
Design:
Prospective interventional study.
Setting:
Academic center.
Participants:
Fifteen obese and 12 normal-weight (NW) eumenorrheic women, ages 2834 years.
Intervention:
Two frequent blood-sampling studies were performed before and after 1 month of omega-3 PUFA
https://www-ncbi-nlm-nih-gov.ccnm.idm.oclc.org/pmc/articles/PMC4701838/?report=printable Page 1 of 18
supplementation with 4 g of eicosapentaenoic acid and docosahexaenoic acid daily.
Main Outcome Measures:

Serum LH and FSH (basal and after GnRH stimulation).
Results:
The ratio of omega-6 to omega-3 PUFA was significantly reduced in plasma and red blood cell
components for both groups after treatment (both P < .01). Omega-3 PUFA supplementation resulted in
reduction of FSH and FSH response to GnRH by 17% on average (P = .06 and P = .03, respectively) in
NW but not obese women. Serum levels of IL-1 and TNF- were reduced after omega-3 PUFA
supplementation (72% for IL-1; 56% for TNF-; both, P < .05) in obese but not in NW women. This
reduction, however, was not associated with a hormonal change in obese women.
Conclusions:
Dietary administration with omega-3 PUFA decreased serum FSH levels in NW but not in obese women
with normal ovarian reserve. This effect is intriguing and is directionally consistent with murine data
whereby higher dietary omega-3 PUFA extends reproductive lifespan. Our results imply that this
nutritional intervention should be tested in women with diminished ovarian reserve in an attempt to delay
ovarian aging.
The United States has the highest prevalence of obesity among all countries surveyed in 2012 by the
Organization for Economic Cooperation and Development (1). It is estimated that by the end of 2015, 41%
of US adults will be obese (2), as defined by a body mass index (BMI) > 30 kg/m2. In women,
reproductive morbidity associated with obesity is considerable and involves anovulation, menstrual cycle
abnormalities, subfertility, fetal loss, obstetrical complications, and congenital anomalies (3). Obesity has
been associated with a state of relative hypogonadotropic hypogonadism, as was shown by animal models
(4) and clinical studies in both women and men (5, 6). A gap in knowledge exists because the mechanisms
underlying these harmful effects are poorly understood, and no specific treatments exist.
Increasing prevalence of obesity in recent decades has been preceded by dramatic dietary changes in
industrialized societies. Over the past 100 years, there has been a considerable shift in the human diet,
particularly with respect to the amount and type of consumed fat. Intake of omega-3 polyunsaturated fatty
acids (PUFAs), previously consumed in large quantities by humans from vegetable and fish sources, has
dwindled (7). The contemporary ratio of dietary omega-6 to omega-3 PUFA is estimated to be as high as
25:1, a drastic change from the 1:1 ratio for previously estimated consumption (8). Dietary fat can have
inflammatory or anti-inflammatory properties based upon its composition. Saturated fats increase plasma
free fatty acids and promote inflammation, whereas omega-3 PUFAs reduce macrophage-induced cytokine
production (9). Recent studies link improved embryo morphology in women (10) and superior oocyte
quality in mice (11) with higher dietary intake of or supplementation with omega-3 PUFA. In animal
studies, diets enriched with omega-3 PUFA enhance early embryonic development (12) and boost
progesterone secretion (13), suggesting that sex steroid metabolism may be affected by modulating PUFA
intake. Despite accumulating evidence of potential benefit in animal studies, the impact of omega-3 PUFA
supplementation on reproductive hormones is unknown. We sought to test whether dietary

supplementation with omega-3 PUFA affects reproductive hormones in women and/or whether this effect
is modulated by body mass.
Subjects and Methods
Participants
Twenty-seven regularly menstruating obese and normal-weight (NW) women were recruited from the
community through campus-wide advertisement and completed the study. The study was approved by
Colorado Multiple Institutional Review Board (13-1420); a signed informed consent was obtained from
each participant before participation. Study criteria included: 1) age, 1842 years; 2) BMI, 30 kg/m2
(obese) or 1825 kg/m2 (NW); 3) history of regular menses every 2540 days; and 4) normal baseline
prolactin, TSH, and blood count. Polycystic ovary syndrome was prospectively ruled out because all
participants were required to have regular menstrual cycles and were nonhirsute; we used the National
Institutes of Health definition of polycystic ovary syndrome, which includes oligomenorrhea as a central
criterion. Participants were excluded if they had allergies to seafood, used medications known to affect
reproductive hormones, used exogenous sex steroids within the last 3 months, exercised vigorously more
than 4 hours weekly, or were attempting pregnancy. All participants had a baseline physical examination
by study personnel and underwent all blood sampling at the Clinical and Translational Research Center of
the Colorado Clinical and Translational Sciences Institute. Pregnancy was excluded by a serum pregnancy
test at the beginning of each month of testing.
Protocol
All women underwent 8 hours of blood sampling every 10 minutes both at baseline and after
approximately 1 month of dietary long chain omega-3 PUFA supplementation (Supplemental Figure 1).
Each frequent blood sampling study was completed during the early follicular phase of the menstrual cycle
(between d 3 and 6) and included iv administration of a physiological, weight-based (75 ng/kg) bolus of
GnRH (Lutrelef; Ferring) given at 6 hours (14). Each participant therefore had a 6-hour window to assess
endogenous LH and FSH secretion before the administration of exogenous GnRH.
Starting with day 1 of the next menstrual cycle after baseline, study participants were instructed to take 4 g
daily of Lovaza (GlaxoSmithKline). This formulation represents a concentrated and purified PUFA
preparation and is approved by the US Food and Drug Administration for treatment of
hypertriglyceridemia (15,17). One gram of Lovaza contains approximately 465 mg of eicosapentaenoic
acid (EPA) and approximately 375 mg of docosahexaenoic acid (DHA) as ethyl esters. The
supplementation continued for two menstrual cycles, and testing started while participants were on their
second cycle of the study. On day 1 of the third menses, participants were scheduled for postintervention
studies, which were completed with an identical frequent blood sampling session as in month 1.
Additionally, daily urinary samples were collected before and after omega-3 supplementation for
measurement of estrogen and progesterone metabolites, and this will be the subject of a separate report.
Hormone assays
Serum LH and FSH were measured using a solid-phase, two-site specific immunofluorometric assay
(DELFIA; Perkin Elmer) (18). Interassay and intra-assay coefficients of variation were 4.8 and 3.4% for
LH, respectively, and 6.6 and 5.0% for FSH, respectively. Ligand Assay and Analysis Core services
(University of Virginia) were used to assay inhibin B and anti-Mllerian hormone (AMH) using
commercial two-site ELISA assays (Beckman Coulter). Functional sensitivity was determined for each
assay (defined as the lowest concentration reliably measured, or the lowest concentration with an
interassay coefficient of variation <20%). Functional sensitivity is 10 pg/mL for inhibin B and 0.16 ng/mL
for AMH. The intra-assay and interassay coefficients of variation were 4.4 and 5.2%, respectively, for
inhibin B, and 3.0 and 7.0%, respectively, for AMH.
Fatty acid composition

Plasma phospholipid and red blood cell (RBC) PUFA composition assessment were obtained for all
subjects at baseline and after dietary supplementation. Phospholipid PUFA composition analysis is a
validated assessment of dietary PUFA intake over a 2- to 3-week period. Whole blood samples were
separated, and plasma was frozen and stored at 80C for later analysis. Plasma and RBC phospholipids
were extracted in methanol and directly methylated with sodium methoxide (25% w/v) using the method
of Glaser et al (19). Fatty acid methyl esters (FAMEs) were extracted in hexanes and separated using
microcapillary gas liquid chromatography with flame ionization detection. Individual FAMEs were
identified by comparison of retention times with known FAME standards. Plasma or RBC PUFA
composition was expressed as a percentage of total PUFA.
Cytokines
Serum proinflammatory cytokine levels were determined using a custom-made 10 cytokines array kit
(RayBiotech) per the manufacturer's instructions (20). For each membrane, 1 mL of serum from each
participant was diluted 1:4 with a blocking buffer and added to the membrane. After incubation and the
addition of antibodies, the array was exposed to x-ray film, and signals were detected using a film
developer. These images were scanned, and average intensities were measured using Quantity One
software (Bio-Rad) after locating signals to antibody array map.
Statistical analysis
The primary outcome measure was the change in the average LH pulse amplitude before and after
administration of omega-3 PUFA. With 10 subjects per group, we had 80% power to detect a change of 0.3
IU/L (or a 37.5% reduction in LH pulse amplitude) using a paired t test with unequal variances assuming a
moderate correlation of 0.5 between the baseline and follow-up outcomes on the same subject. This
change is approximately 40% of the difference between the LH pulse amplitudes of NW and obese patients
in cross-sectional studies (18).
For each study period, LH pulsatility was characterized using the first 6 hours of data before GnRH
administration. LH pulse frequency and amplitude were computed for each individual before and after
omega-3 PUFA using a modified objective pulse detection method that has been previously validated (18,
21). After GnRH administration, for both LH and FSH, mean serum level, peak level, area under the curve
(AUC), and maximum response (the arithmetic difference between the nadir before GnRH and the peak
post GnRH) were evaluated. Baseline characteristics were compared between obese and NW women for
all gonadotropin and PUFA compositions using two-sample t tests, whereas cytokine measures were
compared using the Mann-Whitney test due to skewness. A two-sample t test was used to assess whether
average change in hormonal and demographic measures differed between obese and NW women. Paired t
and Wilcoxon tests were used to assess whether the assessed parameters differed before vs after the
omega-3 PUFA intervention. A P < .05 value was used to denote statistical significance. The analysis was
repeated on change in each of the other measures listed above. Age adjustment was performed to
determine whether a difference in age between NW and obese subjects might have biased the observed
associations of the hormonal outcome measures. For all tested comparisons, the association of the reported
LH and FSH parameters remained similar, and no changes in the level of significance were detected. When
analyzing proinflammatory cytokine levels, no adjustment for multiple comparisons was performed given
the exploratory nature of this analysis. All statistical calculations were performed using R software for
Windows, version 3.1.2.
Results
Biometric and endocrine characteristics

A total of 27 women (15 obese and 12 NW controls) provided complete data for analysis (Table 1).
Although obese women were older (P < .01), there was no significant difference by the main clinical
measure of ovarian reserve, serum AMH. All measures of glucose metabolism/insulin sensitivity (fasting
glucose, fasting insulin, and homeostatic model assessment [HOMA]) were significantly elevated in the
obese group. Inhibin B was significantly lower in the obese women (22% lower on average; P = .049).
Omega-3 treatment did not significantly change any ovarian reserve parameters in either group (Tables 2
and 3). All three measures of glucose metabolism decreased in obese women after treatment with omega-3
PUFA, but this improvement was not statistically significant.
Fatty acid composition

At baseline, the ratio of omega-6 to omega-3 PUFA was similar between the two groups in both plasma
and RBC (P = .36 and P = .51, respectively; Table 1). After omega-3 PUFA supplementation, this ratio
decreased significantly in both NW and obese women by 58 and 55%, respectively, in plasma (Figure 1);
similarly, the ratio in the RBC component decreased by 40 and 36%, respectively (P < .01 for all; Tables 2
and 3). The increase in EPA and DHA (omega-3 PUFA that were directly supplemented) was the greatest.
Plasma EPA increased by 557% in NW and by 443% in obese women, whereas plasma DHA increased by
79% in NW and by 130% in obese women (P < .01 for all). Two subjects in the obese group and one in the
NW group did not have a measurable change in omega-6 to omega-3 PUFA ratio after supplementation. Of
note, these three subjects had the highest and lowest BMI values for our cohort. The two morbidly obese
participants had BMI values of 42.2 and 51.2 kg/m2, respectively, and the NW participant had a BMI of
18.9 kg/m2 (lowest BMI in the cohort). When the analysis was restricted to only those who had changes in
the omega-6 to omega-3 ratio, similar results were seen (data not shown); thus, all data are presented using
the intent-to-treat paradigm for all women who completed the study.
Gonadotropins
At baseline (month 1), during the first 6 hours of unstimulated testing, mean serum LH was lower but was
not significantly different in obese women when compared to NW controls (3.3 0.3 vs 4.4 0.6 IU/L,
respectively; P = .12). Similarly, no significant difference was observed for LH pulse amplitude (1.3 0.1
vs 1.6 0.2 IU/L, respectively; P = .28), LH pulse frequency (3.1 0.4 vs 2.6 0.3 pulses/h, respectively;
P = .33), or GnRH-stimulated gonadotropin levels. Baseline (month 1) FSH parameters were not
statistically different between obese and NW women before or after GnRH.
At month 3 in NW women, both FSH mean level and peak were decreased by 17% vs month 1 studies (4.8
0.3 to 4.0 0.3 IU/L, and 5.5 0.4 to 4.6 0.4 IU/L, respectively), with a trend to statistical
significance (P = .06 for both; Table 2 and Figure 2C). In contrast, no observable change was seen in FSH
parameters before and after dietary supplementation in obese women (Table 3 and Figure 2D). Upon
GnRH stimulation, FSH response has significantly decreased in NW women after omega-3 PUFA
treatment (17% for mean serum level, 17% for AUC, and 19% for peak; P < .05 for all; Table 2 and
Figure 2C). Again, no significant changes were seen in FSH parameters for obese women (Table 3 and
Figure 2D). LH response was not different before or after omega-3 PUFA treatment for either group (
Tables 2 and 3 and Figure 2, A and B). This association of the reported LH and FSH parameters remained
similar, and no changes in the level of significance were detected after adjusting for age.
Proinflammatory cytokines
When examining inflammatory cytokines associated with obesity (20, 22), at baseline, two cytokines
(resistin and IL-12) were significantly higher in obese women compared to NW controls (Figure 3A).
When these measurements were repeated in month 3 of the study after a month of omega-3
supplementation (Figure 3B), all cytokines were decreased in the obese women, with a statistically
significant drop in IL-1 and TNF- (P < .05 for both). No significant changes were seen in cytokines
before and after treatment in NW women, despite reductions in levels ranging from 3482% for some
cytokines.
Discussion
In this interventional study, we have shown that supplementing omega-3 PUFA for at least 4 weeks
resulted in more than a 50% reduction in the endogenous omega-6 to omega-3 ratio, regardless of body
mass. This effect was associated with an improvement in serum IL-1 and TNF- levels, both
proinflammatory cytokines, in obese women. The improvement in the omega-6 to omega-3 ratio in NW
women was associated with a reduction of FSH levels, but there was no significant change in any
measured gonadotropin parameter for obese women.
We have hypothesized that an adiposity-related proinflammatory environment might be responsible for the
relative hypogonadotropic state associated with obesity. Obesity produces a unique inflammatory state that
is low grade and chronic (20, 22, 23). TNF- and IL-1 are known to suppress pituitary LH secretion in
animal studies (24). Many studies have shown this possible association between inflammatory cytokines
and suppression of the hypothalamic-pituitary-ovarian (HPO) axis (25,27). Total omega-3 PUFAs were
observed to be independently associated with lower levels of proinflammatory markers (28, 29). Similar to
our study, clinical studies have shown that supplying 4 g of EPA+DHA and using flaxseed oil rich in -
linolenic acid (omega-3 PUFA) in a dietary framework of an omega-6 to omega-3 ratio of 3:1 or 4:1
resulted in substantial inhibition to the production of IL-1 and TNF- (30, 31). Despite the reduction that
was achieved in both of these inflammatory cytokines in obese participants, our study did not reveal any
significant changes in reproductive endocrinopathy of obesity after the dietary intervention. However,
reducing inflammatory cytokines in obese women could theoretically improve ovarian response to
gonadotropins, resulting in lower FSH and better quality oocytes. A large study of assisted reproduction
demonstrated that inferior pregnancy rates in obese women are normalized when oocytes from NW donors
are transferred into obese recipients (32). Taken together with the rodent data on abnormal oocyte function
and structure in obesity by Moley and others (33, 34), this implies that impaired oocyte quality may
mediate the link between obesity and reproductive impairment, pregnancy complications, and congenital
anomalies. Furthermore, murine diet-induced obesity models demonstrate abnormal oocyte structure and
function with a significant elevation in the inner mitochondrial membrane potential and increased
mitochondrial respiratory chain activity (35). Thus, an alternative and possibly longer intervention may
very well prove effective in improving ovarian responses in obese women and should continue to be
studied.
Improvements in insulin sensitivity and glucose metabolism have been shown to improve reproductive
function in animal models (36). Measures of glucose metabolism improved in this study, although they did
not reach levels of statistical significance, and a larger sample size may be needed to show this effect in
women. There is also evidence that insulin can modulate FSH and LH secretion from the pituitary and
GnRH secretion (36); this should be the subject of future dedicated studies.
Reproductive aging in women is characterized by shortening of menstrual cycles (37), increased oocyte
meiotic spindle abnormalities, and aneuploidy (38, 39), along with declining fertility (40). This phenotype
is classically associated with elevated levels of serum FSH in murine studies (41) and in humans (42, 43).
In an elegant study by Nehra et al (11), it was shown that consumption of a diet rich in omega-3 PUFA
prolonged reproductive lifespan in mice over several generations. Notably, dramatic improvement in egg
quality and ovarian follicle counts was achieved in the advanced maternal age murine model. To
investigate a similar positive effect of an acute dietary treatment with omega-3 PUFA in women, FSH may
be used in proxy to study ovarian reserve in women because circulating FSH levels are responsive to the
endocrine input from the ovary (44). Thus, our study is the first human investigation, to the best of our
knowledge, to test the impact of omega-3 PUFA supplementation on gonadotropins in women. Although
serum AMH appears to be a better marker for ovarian reserve than serum FSH, it is also a less dynamic
hormone with respect to changes over time and changes due to an intervention (45). Our observed changes
in FSH were in concert with animal data (11), in a direction that may indicate a favorable effect on
improving reproductive lifespan. This will need to be investigated in a longer duration of supplementation
and by examining other markers (eg, ovarian follicle counts) to prove this effect. We have measured AMH
before and after supplementation in each group, as reported in Tables 2 and 3. There was no significant
difference in serum AHM after 1 month of supplementation used in our study. A future study of longer
duration should investigate a potential impact over a longer period of time.
Aside from a possible ovarian effect that may explain our observed results, reduction of FSH response to
GnRH suggests a pituitary response. In concert with this argument, animal studies suggest that deteriorated
inflammatory milieu results in suppression of HPO hormones (25,27). However, we have observed a
combination of baseline serum FSH level reduction along with the FSH response to GnRH, which may
indicate a possible reflection of modulated ovarian feedback effect on the central components of the HPO
axis.
Although our contention that reduction in serum FSH may be associated with prolonged reproductive
lifespan in NW women appears to be supported by our detailed experiments, we acknowledge that there is
no evidence that women with hypogonadotropic hypogonadism have a prolonged reproductive lifespan.
However, multiple published studies have documented that hypophysectomized animals tend to have a
longer reproductive lifespan (46), including studies attempting a dietary hypophysectomy (47), a
phenomenon that is not fully understood but is directionally consistent with our results.
Our study was limited by the inability to evaluate oocyte markers. This would be advantageous because
multiple studies demonstrate that impaired oocyte mitochondrial function and structure are markers of
reproductive aging and improved in mouse models (11). This link is thought be partially due to oxidative
stress because mouse models demonstrate dramatic abnormalities of inner mitochondrial membrane
potential and aberrant mitochondrial respiratory chain activity associated with decreased fertility (48).
Omega-3 PUFAs alleviate oxidative stress (49). Thus, the association of improved oocyte quality with
modifications of dietary omega-3 PUFA is well supported by animal studies and laid the groundwork to
investigate the impact of dietary omega-3 PUFAs in women. Our results suggest that omega-3 PUFAs
were associated with consistent reduction of serum FSH in NW women. Elevated serum FSH is a well-
known feature of ovarian aging. Thus, we posit that reduction of serum FSH with increased dietary omega-
3 PUFA is teleologically, mechanistically, and directionally consistent with data in mice. We further posit
that this line of reasoning supports a testable hypothesis that increased dietary omega-3 PUFAs are to be
tested in women in an attempt to delay ovarian aging. The relatively modest sample size and the inability
to evaluate oocyte markers imply that our study should be regarded as hypothesis generating: Does
supplementation with dietary omega-3 PUFA result in delayed ovarian aging? Prospective dedicated
studies are needed to test this hypothesis.
Acknowledgments
We acknowledge the University of Virginia, Center for Research in Reproduction Ligand Assay and
Analysis Core for hormonal assays. We also gratefully acknowledge invaluable advice and guidance of
Nanette Santoro, MD, for proposal preparation and planning. We also gratefully acknowledge invaluable
assistance of Jacob Friedman, PhD and Becky de la Houssaye, MS with cytokine measurement and
interpretation. GnRH was supplied by Ferring Pharmaceuticals.
This work was supported by the Clinical and Translational Sciences Centers at the University of Colorado
School of Medicine 1UL1 RR025780 and by the Eunice Kennedy Shriver National Institute of Child
Health and Human Development/National Institutes of Health (Specialized Cooperative Centers Program
in Reproduction and Infertility Research; Grant to J.W.P., Pilot grant, PI: A.J.P., U54-HD058155).
The authors acknowledge support for this study from the Center for the Study of Reproductive Biology
(Grant U54 HD058155; to A.J.P.). Grant providers had no role in the design, data collection, data analysis,
data interpretation, or writing of the report.
ClinicalTrials.gov Identifier: NCT01894581.
Disclosure Summary: Z.A.A., H.L., N.E.C., J.C., M.H., A.P.B., C.R., R.H.E., and A.J.P. have nothing to
disclose.
Footnotes
Abbreviations:
AMH anti-Mllerian hormone
AUC area under the curve
BMI body mass index
DHA docosahexaenoic acid
EPA eicosapentaenoic acid
FAME fatty acid methyl ester
HOMA homeostatic model assessment
HPO hypothalamic-pituitary-ovarian
NW normal-weight
PUFA polyunsaturated fatty acid
RBC red blood cell.
References
1. Sassi F, Devaux M. Obesity Update 2012. Organization for Economic Cooperation and Development;
http://www.oecd.org/health/49716427.pdf.
2. Wang Y, Beydoun MA. The obesity epidemic in the United Statesgender, age, socioeconomic,
racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol
Rev. 2007;29:628. [PubMed: 17510091]
3. Norman JE. The adverse effects of obesity on reproduction. Reproduction. 2010;140:343345.

[PubMed: 20802106]
4. Todd BJ, Ladyman SR, Grattan DR. Suppression of pulsatile luteinizing hormone secretion but not
luteinizing hormone surge in leptin resistant obese Zucker rats. J Neuroendocrinol. 2003;15:6168.
[PubMed: 12535170]
5. Santoro N, Lasley B, McConnell D, et al. Body size and ethnicity are associated with menstrual cycle
alterations in women in the early menopausal transition: The Study of Women's Health across the Nation
(SWAN) Daily Hormone Study. J Clin Endocrinol Metab. 2004;89:26222631. [PubMed: 15181033]
6. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse
amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese
men. J Clin Endocrinol Metab. 1993;76:11401146. [PubMed: 8496304]
7. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70:560S569S
[PubMed: 10479232]
8. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed
Pharmacother. 2002;56:365379. [PubMed: 12442909]
9. Machtinger R, Combelles CM, Missmer SA, Correia KF, Fox JH, Racowsky C. The association
between severe obesity and characteristics of failed fertilized oocytes. Hum Reprod. 2012;27:31983207.
[PubMed: 22968161]
10. Hammiche F, Vujkovic M, Wijburg W, et al. Increased preconception omega-3 polyunsaturated fatty
acid intake improves embryo morphology. Fertil Steril. 2011;95:18201823. [PubMed: 21130435]
11. Nehra D, Le HD, Fallon EM, et al. Prolonging the female reproductive lifespan and improving egg
quality with dietary omega-3 fatty acids. Aging Cell. 2012;11:10461054. [PubMed: 22978268]
12. Thangavelu G, Colazo MG, Ambrose DJ, Oba M, Okine EK, Dyck MK. Diets enriched in unsaturated
fatty acids enhance early embryonic development in lactating Holstein cows. Theriogenology.
2007;68:949957. [PubMed: 17850856]
13. Wonnacott KE, Kwong WY, Hughes J, et al. Dietary omega-3 and -6 polyunsaturated fatty acids affect
the composition and development of sheep granulosa cells, oocytes and embryos. Reproduction.
2010;139:5769. [PubMed: 19789173]
14. Martin K, Santoro N, Hall J, Filicori M, Wierman M, Crowley WF., Jr Clinical review 15: management
of ovulatory disorders with pulsatile gonadotropin-releasing hormone. J Clin Endocrinol Metab.
1990;71:1081A1081G.
15. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty
acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind,
placebo-controlled study. Clin Ther. 2007;29:13541367. [PubMed: 17825687]
16. Bays HE, Maki KC, McKenney J, et al. Long-term up to 24-month efficacy and safety of concomitant
prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res
Opin. 2010;26:907915. [PubMed: 20156032]
17. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid
effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther.
2008;6:391409. [PubMed: 18327998]
18. Jain A, Polotsky AJ, Rochester D, et al. Pulsatile luteinizing hormone amplitude and progesterone
metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007;92:24682473.
[PubMed: 17440019]
19. Glaser C, Demmelmair H, Koletzko B. High-throughput analysis of fatty acid composition of plasma
glycerophospholipids. J Lipid Res. 2010;51:216221. [PMCID: PMC2789782] [PubMed: 19654422]
20. Heerwagen MJ, Stewart MS, de la Houssaye BA, Janssen RC, Friedman JE. Transgenic increase in N-
3/n-6 fatty acid ratio reduces maternal obesity-associated inflammation and limits adverse developmental
programming in mice. PLoS One. 2013;8:e67791. [PMCID: PMC3692451] [PubMed: 23825686]
21. Rochester D, Jain A, Polotsky AJ, et al. Partial recovery of luteal function after bariatric surgery in
obese women. Fertil Steril. 2009;92:14101415. [PMCID: PMC2818247] [PubMed: 18829008]
22. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415
445. [PubMed: 21219177]
23. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity,
inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:412. [PubMed: 16613757]
24. Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing hormone secretion and ovulation
in the rat. Endocrinology. 1990;127:849856. [PubMed: 2115435]
25. Breen KM, Thackray VG, Hsu T, Mak-McCully RA, Coss D, Mellon PL. Stress levels of
glucocorticoids inhibit LH-subunit gene expression in gonadotrope cells. Mol Endocrinol. 2012;26:1716
1731. [PMCID: PMC3458227] [PubMed: 22851703]
26. Turnbull AV, Rivier C. Inhibition of gonadotropin-induced testosterone secretion by the

intracerebroventricular injection of interleukin-1 in the male rat. Endocrinology. 1997;138:10081013.
[PubMed: 9048602]
27. Ma XC, Chen LT, Oliver J, Horvath E, Phelps CP. Cytokine and adrenal axis responses to endotoxin.
Brain Res. 2000;861:135142. [PubMed: 10751573]
28. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to
circulating inflammatory markers. J Clin Endocrinol Metab. 2006;91:439446. [PubMed: 16234304]
29. Zhao G, Etherton TD, Martin KR, Gillies PJ, West SG, Kris-Etherton PM. Dietary -linolenic acid
inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in
hypercholesterolemic subjects. Am J Clin Nutr. 2007;85:385391. [PubMed: 17284733]
30. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis
Rheum. 1997;27:8597. [PubMed: 9355207]
31. Broughton KS, Johnson CS, Pace BK, Liebman M, Kleppinger KM. Reduced asthma symptoms with
n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr. 1997;65:10111017.
[PubMed: 9094887]
32. Luke B, Brown MB, Missmer SA, Bukulmez O, Leach R, Stern JE. The effect of increasing obesity on
the response to and outcome of assisted reproductive technology: a national study. Fertil Steril.
2011;96:820825. [PubMed: 21821244]
33. Marquard KL, Stephens SM, Jungheim ES, et al. Polycystic ovary syndrome and maternal obesity
affect oocyte size in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril.
2011;95:21462149, 2149.e1. [PMCID: PMC3684964] [PubMed: 21071018]
34. Jungheim ES, Schoeller EL, Marquard KL, Louden ED, Schaffer JE, Moley KH. Diet-induced obesity
model: abnormal oocytes and persistent growth abnormalities in the offspring. Endocrinology.
2010;151:40394046. [PMCID: PMC2940512] [PubMed: 20573727]
35. Igosheva N, Abramov AY, Poston L, et al. Maternal diet-induced obesity alters mitochondrial activity
and redox status in mouse oocytes and zygotes. PLoS One. 2010;5:e10074. [PMCID: PMC2852405]
[PubMed: 20404917]
36. Louden ED, Luzzo KM, Jimenez PT, Chi T, Chi M, Moley KH. TallyHO obese female mice
experience poor reproductive outcomes and abnormal blastocyst metabolism that is reversed by
metformin. Reprod Fertil Dev. 2014;27:3139. [PMCID: PMC4365903] [PubMed: 25472042]
37. Lenton EA, Landgren BM, Sexton L, Harper R. Normal variation in the length of the follicular phase
of the menstrual cycle: effect of chronological age. Br J Obstet Gynaecol. 1984;91:681684.

[PubMed: 6743609]
38. Kuliev A, Zlatopolsky Z, Kirillova I, Spivakova J, Cieslak Janzen J. Meiosis errors in over 20,000
oocytes studied in the practice of preimplantation aneuploidy testing. Reprod Biomed Online. 2011;22:2
8. [PubMed: 21115270]
39. Jones KT. Meiosis in oocytes: predisposition to aneuploidy and its increased incidence with age. Hum
Reprod Update. 2008;14:143158. [PubMed: 18084010]
40. Heffner LJ. Advanced maternal agehow old is too old? N Engl J Med. 2004;351:19271929.
[PubMed: 15525717]
41. Bernstein LR, Mackenzie AC, Kraemer DC, et al. Shortened estrous cycle length, increased FSH
levels, FSH variance, oocyte spindle aberrations, and early declining fertility in aging senescence-
accelerated mouse prone-8 (SAMP8) mice: concomitant characteristics of human midlife female
reproductive aging. Endocrinology. 2014;155:22872300. [PubMed: 24654787]
42. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging:
accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise
in normal older women. J Clin Endocrinol Metab. 1996;81:10381045. [PubMed: 8772573]
43. Lee SJ, Lenton EA, Sexton L, Cooke ID. The effect of age on the cyclical patterns of plasma LH, FSH,
oestradiol and progesterone in women with regular menstrual cycles. Hum Reprod. 1988;3:851855.
[PubMed: 3141454]
44. Elvin JA, Matzuk MM. Mouse models of ovarian failure. Rev Reprod. 1998;3:183195.
[PubMed: 9829553]
45. Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian
hormone in women. Hum Reprod Update. 2014;20:370385. [PubMed: 24430863]
46. Jones EC, Krohn PL. The effect of hypophysectomy on age changes in the ovaries of mice. J
Endocrinol. 1961;21:497509. [PubMed: 13790509]
47. Nelson JF, Gosden RG, Felicio LS. Effect of dietary restriction on estrous cyclicity and follicular
reserves in aging C57BL/6J mice. Biol Reprod. 1985;32:515522. [PubMed: 4039610]
48. Ben-Meir A, Burstein E, Borrego-Alvarez A, et al. Coenzyme Q10 restores oocyte mitochondrial
function and fertility during reproductive aging. Aging Cell. 2015;14:887895. [PMCID: PMC4568976]
[PubMed: 26111777]
49. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative
damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma.
2004;21:14571467. [PubMed: 15672635]
Figures and Tables
Table 1.
Biometric and Endocrine Characteristics in NW and Obese Women at Baseline

a
NW Women Obese Women P
N 12 15
Age, y 28.4 (1.2) 34.8 (1.2) <.01
2
BMI, kg/m 21.8 (0.5) 37.8 (1.5) <.01
Weight, kg 59.3 (1.9) 103.8 (6.6) <.01
Waist circumference, cm 73.6 (2.5) 109.1 (2.7) <.01
Waist-hip ratio 0.89 (0.02) 0.90 (0.01) .43
AMH, ng/mL 5.3 (0.9) 4.2 (0.7) .33
Inhibin B, pg/mL 78.6 (7.2) 61.3 (4.8) .0495
b
Fasting glucose, mg/dL 79.6 (5.5) 90.7 (1.9) .02
b
Fasting insulin, mIU/L 8.8 (1.0) 24.2 (7.7) <.01
c b
HOMA-IR score 1.7 (0.2) 5.5 (1.8) <.01
Plasma N6/N3 ratio 7.7 (0.8) 8.6 (0.4) .36
RBC N6/N3 ratio 5.1 (0.4) 5.4 (0.2) .51
Cycle 1 length, d 27.3 (0.5) 27.6 (0.9) .70
Cycle 2 length, d 28.8 (0.9) 28.5 (1.2) .84
Cycle 3 length, d 28.8 (0.9) 28.1 (1.0) .60
Abbreviations: HOMA-IR, HOMA for insulin resistance; N6/N3, omega-6/omega-3. Values represent mean (standard
error of the mean).
a
P values represent two-sample t test, unless otherwise specified.
b
P values represent Mann-Whitney test.
c
HOMA-IR score is a measure of insulin sensitivity, calculated as follows: fasting insulin fasting glucose/405.
Table 2.
Effect of Omega-3 PUFA Supplementation in NW Women on Reproductive and Metabolic Hormones (n =
12)
a b
Baseline After Omega-3 P
Unstimulated
LH
Mean level, IU/L 4.4 (0.6) 4.1 (0.4) 0.2 (0.7) .77
No. of pulses/h 2.6 (0.3) 2.8 (0.4) 0.3 (0.5) .64
Average pulse amplitude, IU/L 1.6 (0.2) 2.0 (0.4) 0.4 (0.4) .39
FSH
Mean level, IU/L 4.8 (0.3) 4.0 (0.3) 0.8 (0.4) .06
Peak, IU/L 5.5 (0.4) 4.6 (0.4) 0.9 (0.4) .06
GnRH-stimulated
LH
Mean level IU/L 6.5 (0.6) 6.5 (0.6) 0.04 (0.5) .95
c
AUC, IU/L 790 (76) 795 (74) 4.6 (97) .96
Peak, IU/L 9.2 (0.9) 9.0 (0.9) 0.2 (1.0) .84
d
Maximum response, IU/L 6.1 (0.6) 6.1 (0.9) 0.03 (0.7) .96
FSH
Mean level, IU/L 5.2 (0.4) 4.3 (0.3) 0.9 (0.4) .03
c
AUC, IU/L 626 (42) 518 (38) 109 (45) .03
Peak, IU/L 6.0 (0.4) 4.9 (0.4) 1.2 (0.4) .02
d
AMH, ng/mL 5.3 (0.9) 4.7 (0.8) 0.6 (0.7) .36
Inhibin B, pg/mL 78.6 (7.2) 76.5 (8.7) 2.2 (11.3) .85
Fasting glucose, mg/dL 79.6 (5.5) 83.1 (2.2) 3.5 (5.3) .87
Fasting insulin, mIU/L 8.8 (1.0) 9.2 (1.0) 0.33 (1.0) .69
HOMA-IR score 1.7 (0.2) 1.9 (0.2) 0.2 (0.2) .39
Plasma N6/N3 ratio 7.7 (0.8) 3.2 (0.4) 4.5 (0.7) <.01
RBC N6/N3 ratio 5.1 (0.4) 3.0 (0.2) 2.0 (0.3) <.01
error of the mean).
aArithmetic difference between post omega-3 supplement and baseline.
b
P value for comparing values before and after omega-3 supplement in each group.
c
AUC is the sum of concentrations for 120 min (GnRH-stimulated) calculated using the trapezoidal rule.
d
Maximum response to GnRH is defined as the peak level after GnRH bolus minus the lowest value in the hour preceding
GnRH.
Table 3.
Effect of Omega-3 PUFA Supplementation in Obese Women on Reproductive and Metabolic Hormones (n
= 15)
a b
Baseline After Omega-3 P
Unstimulated
LH
Mean level, IU/L 3.3 (0.3) 3.3 (0.3) 0.07 (0.3) .84
No. of pulses/h 3.1 (0.4) 2.8 (0.3) 0.3 (0.6) .64

Average pulse amplitude, IU/L 1.3 (0.1) 1.3 (0.1) 0.04 (0.2) .84
FSH
Mean level, IU/L 4.4 (0.4) 4.2 (0.2) 0.2 (0.3) .51
Peak, IU/L 5.1 (0.4) 5.0 (0.3) 0.1 (0.3) .67
GnRH-stimulated
LH
Mean level
Mean level, IU/L 6.6 (1.0) 6.7 (1.2) 0.2 (0.6) .82
c
AUC, IU/L 821 (121) 836 (150) 14.7 (79) .86
Peak, IU/L 9.7 (1.6) 9.7 (1.9) 0.06 (1.0) .95
d
FSH
Mean level, IU/L 5.1 (0.4) 4.9 (0.3) 0.2 (0.4) .71
c
AUC, IU/L 615 (51) 598 (38) 16.9 (48) .73
Peak, IU/L 5.8 (0.5) 5.6 (0.4) 0.2 (0.4) .61
d
AMH, ng/mL 4.2 (0.8) 3.9 (0.9) 0.3 (0.4) .43
Inhibin B, pg/mL 61.3 (5.6) 65.8 (8.4) 4.5 (7.9) .53
Fasting glucose, mg/dL 90.7 (2.1) 89.4 (3.1) 1.2 (2.0) .50
Fasting insulin, mIU/L 24.2 (8.6) 18.9 (3.1) 5.3 (6.6) .82
HOMA-IR score 5.5 (2.2) 4.1 (0.7) 1.4 (1.6) .93
Plasma N6/N3 ratio 8.6 (0.4) 3.9 (0.4) 4.7 (0.7) <.01
RBC N6/N3 ratio 5.4 (0.2) 3.4 (0.2) 1.9 (0.3) <.01
error of the mean).
a
Arithmetic difference between post omega-3 supplement and baseline
b
P value for comparing values before and post omega-3 supplement treatment in each group
cAUC is sum of concentrations for 120 min (GnRH-stimulated) calculated using trapezoidal rule.
dMaximum response to GnRH is defined as the peak level after GnRH bolus minus the lowest value in the hour preceding
GnRH.
Figure 1.
Impact of omega-3 fatty acid supplementation on plasma omega-6 to omega-3 ratio. Levels in NW and obese women both
at baseline (solid columns) and after 1 month of omega-3 supplementation (striped columns) are shown. Data represent
mean standard error of the mean. *, P < .01.
Figure 2.
Effect of omega-3 PUFA supplementation on serum gonadotropins. LH (A and B) and FSH (C and D) during
unstimulated and GnRH-stimulated portions of frequent blood sampling (GnRH was given after 360 min). Data are from
NW women (green; n = 12) and obese women (red; n = 15) at month 1 (open circles) and month 3 (filled circles). Error
bars indicate standard error of the mean for group composites. , P = .06; *, P = .03.
Figure 3.
Impact of omega-3 PUFA supplementation on serum proinflammatory cytokines. A, Relative baseline cytokine levels.
Data represent mean standard error of the mean at month 1. *, P < .05. B, Change in cytokine levels in response to
treatment. Results are expressed as percentage change in cytokine levels after treatment in month 3.
Articles from The Journal of Clinical Endocrinology and Metabolism are provided here courtesy of The
Endocrine Society

Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal Weight But Not Obese Women

Încărcat de

Informații document

Titlu original

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal Weight But Not Obese Women

Încărcat de

Drepturi de autor:

Formate disponibile

Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal Weight But Not Obese Women 2017-03-29, 9*11 AM

J Clin Endocrinol Metab. 2016 Jan; 101(1): 324333. PMCID: PMC4701838

Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal

Received 2015 Jul 17; Accepted 2015 Oct 23.

Copyright 2016 by the Endocrine Society

supplementation with 4 g of eicosapentaenoic acid and docosahexaenoic acid daily.

Main Outcome Measures:

supplementation on reproductive hormones is unknown. We sought to test whether dietary

Subjects and Methods

Fatty acid composition

Biometric and endocrine characteristics

Fatty acid composition

ClinicalTrials.gov Identifier: NCT01894581.

3. Norman JE. The adverse effects of obesity on reproduction. Reproduction. 2010;140:343345.

26. Turnbull AV, Rivier C. Inhibition of gonadotropin-induced testosterone secretion by the

of the menstrual cycle: effect of chronological age. Br J Obstet Gynaecol. 1984;91:681684.

Figures and Tables

Biometric and Endocrine Characteristics in NW and Obese Women at Baseline

No. of pulses/h 3.1 (0.4) 2.8 (0.3) 0.3 (0.6) .64

S-ar putea să vă placă și